Continued JAK Inhibitor Treatment on the Risk of Recurrent Herpes Zoster Reactivation in Patients with Immune-mediated Inflammatory Diseases: A Nationwide Population-based Study in South Korea
Semin Arthritis Rheum 2024 doi 10.1016/j.semarthrit.2024.152362 Epub ahead of print
This real-world study by Kim, et al. found no significant relationship between continued JAK inhibitor therapy in patients with IMIDs and the risk of subsequent recurrent HZ reactivation. They also found no significant difference in the number of days patients were treated for HZ in the JAK inhibitor continuation and discontinuation groups.